Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -1371.56% is 19% below its 3-year average of -1148.21%, near the low end of its 3-year range (-4817.73%–8496.24%).
255.28% below its 12-month average of 883.27%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -1065.73%.
EBITDA MARGIN
-1371.56%
EBITDA MARGIN AVG TTM
883.27%
EBITDA MARGIN AVG 3Y
-1075.08%
EBITDA MARGIN AVG 5Y
-1148.21%
EBITDA MARGIN AVG 10Y
-982.28%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-255.28%
CURRENT VS 3Y AVG
-27.58%
CURRENT VS 5Y AVG
-19.45%
CURRENT VS 10Y AVG
-39.63%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Ocugen, Inc.
Market Cap
$359.46M
EBITDA Margin
-1371.56%
TTM Avg
883.27%
3Y Avg
-1075.08%
5Y Avg
-1148.21%
Market Cap
$364.53M
EBITDA Margin
-271.53%
TTM Avg
-418.08%
3Y Avg
-211.46%
5Y Avg
-940.00%
Market Cap
$356.58M
EBITDA Margin
-13.98%
TTM Avg
-3.54%
3Y Avg
-384.69%
5Y Avg
-2364.58%
Market Cap
$355.92M
EBITDA Margin
-25837.05%
TTM Avg
-12960.93%
3Y Avg
-7440.06%
5Y Avg
-7440.06%
Market Cap
$355.05M
EBITDA Margin
-870.38%
TTM Avg
-506.32%
3Y Avg
-506.32%
5Y Avg
-506.32%
Market Cap
$355.18M
EBITDA Margin
-122.86%
TTM Avg
-149.66%
3Y Avg
-152.47%
5Y Avg
-125.05%
Market Cap
$352.32M
EBITDA Margin
-153.75%
TTM Avg
-1289.79%
3Y Avg
-1338.35%
5Y Avg
-1135.96%
Market Cap
$374.87M
EBITDA Margin
-12.87%
TTM Avg
-20.20%
3Y Avg
-216.20%
5Y Avg
-209.97%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocugen, Inc. (OCGN) | $359.46M | -1371.56% | 883.27% | -1075.08% | -1148.21% |
| Opus Genetics, Inc. (IRD)vs › | $364.53M | -271.53% | -418.08% | -211.46% | -940.00% |
| Embecta Corp. (EMBC)vs › | $357.28M | 35.21% | 27.25% | 28.55% | 34.67% |
| Fennec Pharmaceuticals Inc. (FENC)vs › | $356.58M | -13.98% | -3.54% | -384.69% | -2364.58% |
| Artiva Biotherapeutics, Inc. (ARTV)vs › | $355.92M | -25837.05% | -12960.93% | -7440.06% | -7440.06% |
| Relmada Therapeutics, Inc. (RLMD)vs › | $355.05M | -870.38% | -506.32% | -506.32% | -506.32% |
| Enanta Pharmaceuticals, Inc. (ENTA)vs › | $355.18M | -122.86% | -149.66% | -152.47% | -125.05% |
| Orchestra BioMed Holdings, Inc. (OBIO)vs › | $352.32M | -153.75% | -1289.79% | -1338.35% | -1135.96% |
| Canopy Growth Corporation (CGC)vs › | $374.87M | -12.87% | -20.20% | -216.20% | -209.97% |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $376.04M | -107.01% | -86.79% | -53.66% | -431.14% |
Gross Margin
45.9%
EBITDA Margin
-1371.6%
Operating Margin
-1425.7%
Net Margin
-1786.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -1065.73% |
| 2026-03-31 | -1125.18% |
| 2025-12-31 | 8496.24% |
| 2025-09-30 | -951.77% |
| 2025-06-30 | -937.22% |
| 2025-03-31 | -917.76% |
| 2024-12-31 | -1733.25% |
| 2024-09-30 | -1112.59% |
| 2024-06-30 | -1303.33% |
| 2024-03-31 | -1187.08% |
| 2023-12-31 | -139.89% |
| 2023-09-30 | -331.28% |
| 2023-06-30 | -4817.73% |
| 2023-03-31 | -4031.83% |
| 2020-06-30 | -7781.40% |
| 2013-09-30 | -137533.33% |
